(Press-News.org) Boston, MA – Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitaliization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.
The study will be published April 10, 2014 in the New England Journal of Medicine.
"There currently are no existing therapies to address the prognoses of the approximately 40 percent of patients with heart failure and a preserved ejection fraction," said Eldrin Lewis, MD, advanced heart failure specialist, Brigham and Women's Hospital (BWH) Division of Cardiovascular Medicine, Department of Medicine, study co-author. "TOPCAT is the first randomized, double-blind trial to assess the effect of a treatment—spironolactone—on clinical outcomes in this patient demographic."
"TOPCAT was robust in its design and was well-conducted, with a strong collaboration between the New England Research Institutes and clinical colleagues at Brigham and Women's Hospital and the University of Michigan, thus ensuring that the results would be reliable," said Sonja McKinlay PhD, president of New England Research Institutes, study co-senior author.
The TOPCAT trial enrolled 3,445 patients from 233 medical sites in six countries. Participants with symptomatic heart failure and a left ventricular ejection fraction of 45 percent or more (normal or near normal contractions) were randomized to receive either spironolactone (15 to 45 milligrams daily) or matching placebo, and were followed for an average of nearly 3.3 years.
The primary outcome consisted of death from cardiovascular causes, surviving a cardiac arrest, or hospitalization for the management of heart failure—whichever happened first—and occurred in 320 of 1,722 patients in the spironolactone group (18.6 percent) and 351 of 1,723 patients in the placebo group (20.4 percent).
Spironolactone belongs to a class of medications known as aldosterone receptor antagonists. Spironolactone is used to treat fluid retention in patients with congestive heart failure, liver cirrhosis or nephrotic syndrome. It is also used to treat high blood pressure, heart failure and low blood potassium (hypokalemia).
Looking at the components of the primary outcome separately, only hospitalizations, specifically for heart failure, had a significantly lower incidence for those taking spironolactone compared to placebo, with 206 patients (12.0 percent) in the spironolactone group undergoing hospitalization versus 245 patients (14.2 percent) in the placebo group.
"While the overall results failed to demonstrate a significant effect of spironolactone on the primary endpoint in TOPCAT, the study provides important insights into the potential efficacy of spironolactone in reducing the need for hospitalizations for heart failure in this population, as well as providing clues for more effectively designing future studies to reduce mortality," said Bertram Pitt, MD, University of Michigan School of Medicine, study co-senior author.
Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone. There were no significant differences in the incidence of serious adverse events. However, spironolactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (high potassium concentration in the blood), but conversely led to reduced hypokalemia (low potassium concentration in the blood). According to the researchers, such findings underscore the importance of monitoring patients prescribed spironolactone.
"When treating patients, clinicians must balance risks and benefits," said Marc A. Pfeffer, MD, PhD, BWH Division of Cardiovascular Medicine, Department of Medicine, study co-senior author. "If clinicians decide to prescribe spironolactone to their patients to reduce their risk of being hospitalized for heart failure, there is an associated responsibility to monitor for serum markers of kidney and electrolyte disorders which can be exacerbated by spironolactone."
INFORMATION:
This research was supported by the National Heart, Lung and Blood Institute, National Institutes of Health (HHSN268200425207C).
Lewis reports receiving grant support from Novartis, Amgen, and Sanofi-Aventis. Pfeffer reports receiving consulting fees and grant support from Amgen, consulting fees from Aastrom Biosciences, Abbott Vascular, Cerenis Therapeutics, Concert Pharmaceuticals, FibroGen, GlaxoSmithKline, Medtronic, Merck, Roche, Servier, and Teva Pharmaceuticals,
and grant support from Celladon, Novartis, and Sanofi-Aventis and being a coinventor on patents related to the use of inhibitors of the renin-angiotensin system in selected survivors of myocardial infarction, which are licensed to Novartis and Boehringer Ingelheim (5,972,990 and 5,977,160). Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
ABOUT TOPCAT Trial
TOPCAT is a multi-center, international, randomized, double-blind, placebo-controlled trial of the aldosterone antagonist, spironolactone, in 3,445 adult subjects with heart failure and left ventricular ejection fraction of at least 45 percent, recruited internationally from over 200 clinical centers in the United States, Canada, Russia, Republic of Georgia, Argentina and Brazil.
The TOPCAT trial was led by a clinical research team at Brigham and Women's Hospital under the direction of Marc A. Pfeffer, MD, PhD, BWH Division of Cardiovascular Medicine, Department of Medicine, in collaboration with the New England Research Institutes, directed by Sonja McKinlay, PhD. The rationale for using spironolactone—an inexpensive, generic, medication—stems from the pioneering research of Bertram Pitt, MD, University of Michigan School of Medicine, who showed the benefit of this class of drugs in patients with heart failure and reduced ejection fraction, and who also served as chair of the TOPCAT Steering Committee.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.
Spironolactone not reduce primary outcome, did reduce hospitalizations for heart failure
2014-04-10
ELSE PRESS RELEASES FROM THIS DATE:
Study confirms impact of clinician-patient relationship on health outcomes
2014-04-10
A meta-analysis of studies that investigated measures designed to improve health professionals' interactions with patients confirms that such efforts can produce health effects just as beneficial as taking a daily aspirin to prevent heart attack. In contrast to previous such reviews, the current report from the Empathy and Relational Science Program at Massachusetts General Hospital (MGH) only included randomized, controlled trials with more reliable results than those included in earlier studies. While it has long been believed that a good patient-clinician relationship ...
Water users can reduce the risk of spreading invasive species
2014-04-10
Foreign species that are devastating water ecosystems could be "hitchhiking" around Britain on canoeists' and anglers' kit, according to a new study.
Invaders like the killer shrimp, zebra mussel and American signal crayfish have already caused extensive environmental damage and millions of pounds of economic costs.
The new research, led by the University of Leeds and the Centre for Environment Fisheries and Aquaculture Science (Cefas), found that the cleaning habits of anglers and canoeists could be a key part of the problem.
The study, based on a survey of more ...
Butterfly larvae mimic queen ant to avoid detection
2014-04-10
Parasitic butterfly larvae may mimic ants' acoustic signals to aid in the infiltration of their host colonies, according to results published April 9, 2014, in the open access journal PLOS ONE by Marco Sala from University of Turin, Italy, and colleagues.
Ants aggressively defend their colonies and nests, so successfully that these locations make a perfect shelter for another similar species to live in. However, ants have evolved a complex set of signals that allow colony members to distinguish between residents and intruders. The social parasitic Maculinea butterfly uses ...
Security barriers in US/Mexico national parks affect movement of animals
2014-04-10
Because international boundaries can be focal points for trade, illegal activity and development, national parks in their vicinity can be vulnerable to pollution, erosion and hunting as well as smuggling of people and drugs.
There is an increasing trend towards the erection of barriers to counter this illegal activity, which may reduce environmental impacts too. However barriers may restrict native species' territory, causing an environmental impact of their own.
Bristol PhD student, Jamie McCallum, now of the Zoological Society of London (ZSL), and colleagues from ...
Genetic defect may confer resistance to certain viral infections
2014-04-10
WHAT:
A National Institutes of Health (NIH) study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections. Researchers found that HIV and influenza viruses replicate in the cells of people with congenital disorder of glycosylation type IIb (CDG-IIb) at a much lower rate than in healthy donor cells, creating fewer and less infectious viruses. The study, published in The New England Journal of Medicine, was led by Sergio Rosenzweig, M.D., Ph.D., director of ...
Consuming a high-fat diet is associated with increased risk of certain types of BC
2014-04-09
High total and saturated fat intake were associated with greater risk of estrogen receptor- and progesterone receptor-positive (ER+PR+) breast cancer (BC), and human epidermal growth factor 2 receptor-negative (HER2-) disease, according to a new study published April 9 in the Journal of the National Cancer Institute.
Published data from epidemiological and case-control studies on the association between high fat intake and BC risk have been conflicting, which may be attributable to difficulties obtaining accurate information on fat intake and because of limited heterogeneity ...
Older people with faster decline in memory/thinking skills may have lower risk of cancer death
2014-04-09
MINNEAPOLIS – Older people who are starting to have memory and thinking problems, but do not yet have dementia may have a lower risk of dying from cancer than people who have no memory and thinking problems, according to a study published in the April 9, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.
"Studies have shown that people with Alzheimer's disease are less likely to develop cancer, but we don't know the reason for that link," said study author Julián Benito-León, MD, PhD, of University Hospital 12 of October in Madrid, ...
Physical activity associated with lower rates of hospital readmission in patients with COPD
2014-04-09
PASADENA, Calif., April 9, 2014 — Patients with chronic obstructive pulmonary disease (COPD) who participated in any level of moderate to vigorous physical activity had a lower risk of hospital readmission within 30 days compared to those who were inactive, according to a study published today in the Annals of the American Thoracic Society.
Researchers examined the electronic health records of 6,042 Kaiser Permanente patients in Southern California who were 40 years or older and who were hospitalized with COPD between Jan. 1, 2011 and Dec. 31, 2012. As part of Kaiser ...
Patients over 65 have more complications after colorectal cancer surgery
2014-04-09
Bottom Line: Most colorectal cancer surgeries are performed on patients older than 65 years, and older patients have worse outcomes than younger patients, although the total number of colon cancer operations has decreased in the past decade.
Author: Mehraneh D. Jafari, M.D., and colleagues from the University of California, Irvine School of Medicine, Orange.
Background: Gastrointestinal cancers are common in the elderly with peak occurrences in the sixth and seventh decades of life. Colorectal cancer (CRC) is a leading cause of death and surgery remains the curative ...
Scientists firm up origin of cold-adapted yeasts that make cold beer
2014-04-09
MADISON, Wis. — As one of the most widely consumed and commercially important beverages on the planet, one would expect the experts to know everything there is to know about lager beer.
But it was just a few years ago that scientists identified the South American yeast that, hundreds of years ago, somehow hitched a ride to Bavaria and combined with the domesticated Old World yeast used for millennia to make ale and bread to form the hybrid that makes lager or cold stored beer.
The mystery of the cold-adapted yeast that blended with a distant cousin to make the lager-churning ...